<unk> , sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.<unk>  is designed to attach to the spike protein of SARS-CoV-2. The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.
Sotrovimab
Atoltivimab
Odesivimab
Obiltoxaximab
Regdanvimab
Maftivimab
Nirsevimab
Bebtelovimab